Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.
about
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Site-specific PEGylation of an ...... proves its antitumor efficacy.
@en
Site-specific PEGylation of an ...... proves its antitumor efficacy.
@nl
type
label
Site-specific PEGylation of an ...... proves its antitumor efficacy.
@en
Site-specific PEGylation of an ...... proves its antitumor efficacy.
@nl
prefLabel
Site-specific PEGylation of an ...... proves its antitumor efficacy.
@en
Site-specific PEGylation of an ...... proves its antitumor efficacy.
@nl
P2093
P2860
P356
P1476
Site-specific PEGylation of an ...... mproves its antitumor efficacy
@en
P2093
Haitao Pan
Jieyu Xing
Wentong Deng
Zhong Wang
P2860
P304
P356
10.2147/IJN.S164542
P407
P50
P577
2018-05-29T00:00:00Z